Rational combination immunotherapeutic approaches for effective cancer treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cao Dai Phung | - |
dc.contributor.author | Hanh Thuy Nguyen | - |
dc.contributor.author | Tuan Hiep Tran | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Yong, Chul Soon | - |
dc.contributor.author | Kim, Jong Oh | - |
dc.date.accessioned | 2021-06-22T10:26:04Z | - |
dc.date.available | 2021-06-22T10:26:04Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/3554 | - |
dc.description.abstract | Immunotherapy is an important mode of cancer treatment. Over the past decades, immunotherapy has improved the clinical outcome for cancer patients. However, in many cases, mutations in cancer cells, lack of selectivity, insufficiency of tumor-reactive T cells, and host immunosuppression limit the clinical benefit of immunotherapy. Combination approaches in immunotherapy may overcome these obstacles. Accumulating evidence demonstrates that combination immunotherapy is the future of cancer treatment. However, designing safe and rational combinations of immunotherapy with other treatment modalities is critical. This review will discuss the optimal immunotherapy-based combinations mainly with respect to the mechanisms of action of individual therapeutic agents that target multiple steps in evasion and progression of tumor. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.title | Rational combination immunotherapeutic approaches for effective cancer treatment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Han-Gon | - |
dc.identifier.doi | 10.1016/j.jconrel.2018.12.020 | - |
dc.identifier.scopusid | 2-s2.0-85058446880 | - |
dc.identifier.wosid | 000455852000009 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.294, pp.114 - 130 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 294 | - |
dc.citation.startPage | 114 | - |
dc.citation.endPage | 130 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | REGULATORY T-CELLS | - |
dc.subject.keywordPlus | DOSE RECOMBINANT INTERLEUKIN-2 | - |
dc.subject.keywordPlus | LONG-TERM SURVIVAL | - |
dc.subject.keywordPlus | IMMUNE CHECKPOINT BLOCKADE | - |
dc.subject.keywordPlus | ANTITUMOR IMMUNITY | - |
dc.subject.keywordPlus | METASTATIC MELANOMA | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | IMMUNOSUPPRESSIVE NETWORKS | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE AUGMENTS | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Combination | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0168365918307235?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.